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ABSTRACT 
Non-alcoholic fatty liver disease (NAFLD) is a severe liver disease that is increasing in preva-
lence with the worldwide epidemic of obesity and its related insulin-resistance state. Evidence 
for the role of the gut microbiota in energy storage and the subsequent development of obesity 
and some of its related diseases is now well established. More recently, a new role of gut mi-
crobiota has emerged in NAFLD. The gut microbiota is involved in gut permeability, low-
grade inflammation and immune balance, it modulates dietary choline metabolism, regulates 
bile acid metabolism and produces endogenous ethanol. All of these factors are molecular 
mechanisms by which the microbiota can induce NAFLD or its progression toward overt non-
alcoholic steatohepatitis. Modification of the gut microbiota composition and/or its biochemi-
cal capacity by specific dietary or pharmacological interventions may advantageously affect 
host metabolism. Large-scale intervention trials, investigating the potential benefit of prebiot-
ics and probiotics in improving cardiometabolic health in high-risk populations, are fervently 
awaited. 
 
Keywords: Gut microbiome, NAFLD, interventions 
 
INTRODUCTION 
The rising incidence of obesity in to-
day’s environment is associated with many 
obesity-related health complications, in-
cluding cardiovascular disease, type 2 dia-
betes (T2D), hyperlipidemia, hypertension, 
and nonalcoholic fatty liver disease 
(NAFLD) (Tarantino et al., 2007; 2012; 
2013; Finelli and Tarantino, 2013a). This 
constellation is also recognized as the met-
abolic syndrome and is characterized by 
underlying insulin resistance (IR). NAFLD 
or generally speaking hepatic steatosis (HS) 
is defined as the accumulation of lipid, pri-
marily in the form of triacylglycerols in in-
dividuals who do not consume significant 
amounts of alcohol (< 20 g ethanol/d) and 
in whom other known causes of steatosis, 
such as certain drugs and toxins, have been 
excluded (Vuppalanchi and Chalasani, 
2009). The spectrum of NAFLD includes 
simple fatty liver, non alcoholic steatohepa-
titis (NASH) - characterized by inflamma-
tion, apoptosis, ballooning degeneration, 
Mallory hyaline, fibrosis-, cirrhosis post 
NASH, hepatocellular carcinoma and ad-
vanced liver disease, which leads to liver-
related death (Vuppalanchi and Chalasani, 
2009; Sorrentino et al., 2004; Tarantino and 
Finelli, 2013; Tarantino, 2007; Tarantino et 
al., 2011a; Finelli and Tarantino, 2013c). 
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Given the close relations between obesi-
ty, the metabolic syndrome, and the devel-
opment of NAFLD, it is not surprising that 
many NAFLD patients have multiple com-
ponents of the metabolic syndrome, wheth-
er or not they are overweight or obese. IR is 
present in and is a significant predictor of 
NAFLD and NASH in most patients (Clark, 
2006), even the ~ 10–15 % of patients who 
are not overweight (Chiang et al., 2011; 
Hamaguchi et al., 2012). NAFLD is a mul-
tifactorial disease that involves a complex 
interaction of genetics, diet, and lifestyle, 
all of which combine to form the NAFLD 
phenotype. A cornerstone of the manage-
ment strategy in such patients with fatty 
liver is the use of diet to decrease body 
weight, and improve glycemic control, 
dyslipidemia and cardiovascular risks as 
well (Finelli and Tarantino, 2012b).  
Gut microbiota are thought to play a 
role in the pathogenesis of NASH for sev-
eral reasons. First, gut microbiota are 
known to have a large effect on the diges-
tion and absorption of nutrients (van der 
Hoeven-Hangoor et al., 2013). Microbiota 
transplantation experiments in mice sug-
gested that certain microbiota is capable of 
inducing obesity independent of other envi-
ronmental factors (Kallus and Brandt, 
2012). Second, gut microbiota participate in 
the development and homeostasis of the 
overall immunity of the host (Gigante et al., 
2011). Therefore, certain microbiota may 
influence the development of liver inflam-
mation. The links between gut microbiota 
and the host immune system include TLRs 
and short-chain fatty acids (Vinolo et al., 
2011). In fact, the innate immune system 
might influence the metabolic syndrome 
and obesity, as mice deficient in Toll-like 
receptor 5 develop hyperphagia, become 
obese and insulin resistant (Tilg, 2010). 
Third, gut microbiota may influence the 
production of gut hormones, such as gluca-
gon-like peptide 1, and, subsequently, have 
an effect on the overall metabolism of the 
host (Flint, 2011). 
The liver appears as the first point of 
contact for (and produces the initial immu-
nological response to) bacteria and micro-
bial components, as well as other endoge-
nous and exogenous toxins present in the 
portal blood. Given the capacity of the liver 
to regulate metabolism in a form that can 
affect the entire organism, to distribute nu-
merous substances to the gut through bile 
and the entero hepatic circulation, and to 
regulate numerous hormonal and immuno-
logical responses, the potential for the liver 
to influence gut function can be quickly ap-
preciated. Interactions between the gut, the 
diet and the liver are, naturally, bidirection-
al; hormones, inflammatory mediators and 
the products of digestion and absorption all 
unequivocally influence liver function. The 
focus of this review is on gut–liver-diet in-
teractions that contribute to the pathogene-
sis of a common liver disorder, NAFLD. 
 
Interactions between the intestinal micro-
biota and liver 
The interactions of the gut microbiota 
and the liver have only recently been inves-
tigated in detail. Receiving approximately 
70 % of its blood supply from the intestinal 
venous outflow, the liver represents the first 
line of defense against gut-derived antigens, 
food antigens, toxins, microbial-derived 
products, and microorganisms (Henao-
Mejia et al., 2013). The liver, therefore, is 
equipped with a broad array of immune 
cells (i.e., macrophages, lymphocytes, natu-
ral killer cells, and dendritic cells) to ac-
complish this function (Henao-Mejia et al., 
2013). Small intestinal bacterial overgrowth 
(SIBO) is common in patients with cirrho-
sis (Wiest et al., 2014; Savarino et al., 
2011; Bellot et al., 2013; Gupta et al., 2010) 
and its prevalence correlates directly with 
the severity of liver disease (Pande et al., 
2009). A physiological basis for SIBO in 
liver disease was added by reports of im-
paired small bowel motility and prolonged 
orocecal transit time in patients with cirrho-
sis (Seo and Shah, 2012; Gunnarsdottir et 
al., 2003). Some studies reinforced the con-
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cept that disturbed motility predisposes to 
SIBO, and suggested a link between altera-
tions in intestinal motility and the develop-
ment of both hepatic encephalopathy and 
spontaneous bacterial peritonitis (Romeiro 
et al., 2013; Ancel et al., 2006; Bouin et al., 
2004; Garcovich et al., 2012). Bacterial 
translocation (passage of viable bacteria re-
sident in the gastrointestinal tract to gener-
ally sterile tissues) in the context of SIBO is 
facilitated by augmented intestinal permea-
bility, another feature of liver cirrhosis 
(Hada et al., 2010; Cariello et al., 2010). 
Indeed, increased intestinal permeability is 
associated with an increased risk of sponta-
neous bacterial peritonitis (Benjamin et al., 
2013; Assimakopoulos et al., 2012). 
Having identified bacterial products as 
hepatotoxins (Lamontagne et al., 2013; 
Kisch et al., 2006) and having figured out 
that multiple metabolic activities of the gut 
microbiota could affect the liver function, 
the potential for the gut microbiota to indu-
ce or maintain various liver diseases, main-
ly at the light of its immunological interac-
tions with the host has been clearly reck-
oned. 
 
Nafld, intestinal microbiota and metabolic 
changes 
NAFLD is a multifactorial disease. 
Numerous genetic, metabolic, inflammatory 
and environmental factors are consideration 
to contribute to its pathogenesis (Figure 1). 
In the middle of the environmental factors, 
diet is the most important, though its role 
may be more complex than one of simply 
inducing fat accumulation in the liver, and 
may involve interactions with the microbio-
ta. indeed, the microbiota may contribute to 
NAFLD in a number of ways, some of 
which are quite unexpected. 
 
Obesity 
Obesity, especially visceral obesity, is a 
major risk factor for NAFLD in humans 
(Finelli and Tarantino, 2012a). The gut mi-
crobiota is partly responsible for body fat 
deposition in mice (Flint, 2011). Usually 
colonized animals have a higher body fat 
content than do germfree animals; the inoc-
ulation of germfree mice with micro biota 
obtained from usually colonized adult ani-
mals resulted in a 57 % increase in total 
body fat (Wolf, 2006). Organisms in the 
Bacteroidetes and Firmicutes phyla collec-
tively represent about 90 % of the micro-
biota composition in mice, as they do in 
humans (Murphy, 2010). However, their 
relative contributions vary considerably ac-
cording to body composition. In a murine 
model, it was shown that the relative abun-
dance of these two phyla differs among lean 
and obese mice; the obese mouse had a 
higher proportion of Firmicutes to Bacteroi-
detes (50 % greater) than the lean mouse 
(Kallus and Brandt, 2012). The same results 
were appreciated in obese humans com-
pared to lean subjects, as reported by Kallus 
and Brandt (2012). The postulated explana-
tion for this finding is that Firmicutes pro-
duce more complete metabolism of a given 
energy source than do Bacteroidetes, thus 
promoting more efficient absorption of cal-
ories and subsequent weight gain (Kallus 
and Brandt, 2012). These findings indicate 
a possible role for components of the mi-
crobiota in determining the efficiency of 
calorie extraction from the diet and, there-
by, influencing body weight (Blaut and 
Klaus, 2012). It showed that the significant 
increase in mannitol excretion rate, in pa-
tients undergoing Roux-en-Y Gastric By-
pass (RYGB), from the first postoperative 
month to the sixth postoperative month 
most likely reflects the occurrence of intes-
tinal adaptation (mucosal hyperplasia), 
which would tend to minimize the malab-
sorption of macronutrients (Savassi-Rocha 
et al., 2014). A subgroup of patients who 
undergo RYGB exhibit pronounced in-
crease in their intestinal permeability (as-
sessed by the lactulose/mannitol ratio and 
the lactulose excretion rate) at the sixth 
postoperative month (Savassi-Rocha et al., 
2014). Obese humans harbour considerably 
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Figure 1: Effects of the gut microbita on pathogenesis of NAFLD 
(Abbreviations: LPS – lipopolysaccharide; VLDL – very-low-density lipoprotein) 
 
fewer Bacteroidetes and more Firmicutes 
than lean controls (Krznarić et al., 2012). 
Changes in the gut microbiota have also 
been documented among obese individuals 
after gastric bypass surgery (Osto et al., 
2013). Osto et al. (2013) showed that 
RYGB surgery might differently modify the 
gut microbiota composition in the three dis-
tinct anatomical sections of the small intes-
tine compared to sham surgery. RYGB in-
duced changes in the microbiota of the ali-
mentary limb and the common channel re-
sembling those seen after prebiotic treat-
ment or weight loss by dieting, as reported 
by Osto et al. (2013). These changes may 
be associated with altered production of in-
testinal hormones known to control energy 
balance (Osto et al., 2013). Postsurgical 
modulation of gut microbiota may signifi-
cantly contribute to the beneficial metabolic 
effects of RYGB surgery (Osto et al., 
2013), not excluding those on NAFLD. 
Santacruz et al. (2009) indicated that 
calorie restriction and physical activity have 
an impact on gut microbiota composition 
related to body weight loss, which also 
seem to be influenced by the individual's 
microbiota. Limited evidence suggests a 
role for increased microbial extraction of 
calories among obese humans. DiBaise et 
al. (2008), in their review, suggests that the 
gut microbiota affects nutrient acquisition 
and energy regulation and its composition 
has also been shown to differ in lean vs 
obese animals and humans. Some evidence 
suggests that the metabolic activities of the 
gut microbiota facilitate the extraction of 
calories from ingested dietary substances 
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and help to store these calories in host adi-
pose tissue for later use (DiBaise et al., 
2008). Furthermore, the gut bacterial flora 
of obese mice and humans include fewer 
Bacteroidetes and correspondingly more 
Firmicutes than that of their lean counter-
parts, suggesting that differences in caloric 
extraction of ingested food substances may 
be due to the composition of the gut micro-
biota (DiBaise et al., 2008). Bacterial lipo-
polysaccharide derived from the intestinal 
microbiota may act as a triggering factor 
linking inflammation to high-fat diet-
induced metabolic syndrome (DiBaise et 
al., 2008). DiBaise et al. (2008) concluded 
that existing evidence warrants further in-
vestigation of the microbial ecology of the 
human gut and points to modification of the 
gut microbiota as one means to treat people 
who are over-weight or obese.  
Several studies reveal how the microbi-
ota might influence body weight and com-
position. Gut microbiota could precisely af-
fect the proportion of calories obtained 
from the intestinal contents (caloric sal-
vage). For example, Bacteroides thetai-
otamicron is able to break most glycosidic 
linkages of numerous constituents of our 
diet. This Gram-negative anaerobic bacte-
rium can degrade indigestible poly saccha-
rides from plant, representing a quota part 
of calorie needs, nearly 10–15 % (Zocco et 
al., 2007). Furthermore, microbes are pre-
dominantly found in surface-attached and 
spatially structured polymicrobial commu-
nities (Estrela and Brown, 2013). Within 
these communities, microbial cells excrete 
a wide range of metabolites, setting the 
stage for interspecific metabolic interac-
tions (Estrela and Brown, 2013). The links, 
however, between metabolic and ecological 
interactions (functional relationships), and 
species spatial organization (structural rela-
tionships) are still poorly understood, as re-
ported by Estrela et al. (2013). It showed 
that strong metabolic interdependence 
drives the emergence of mutualism, robust 
interspecific mixing, and increased com-
munity productivity. These emergent com-
munity properties are driven by demograph-
ic feedbacks, such that aid from neighbor-
ing cells directly enhances focal cell 
growth, which in turn feeds back to neigh-
bour fecundity. In contrast, weak metabolic 
interdependence drives conflict (exploita-
tion or competition), and in turn greater in-
terspecific segregation. Together, these re-
sults support the idea that species structural 
and functional relationships represent the 
net balance of metabolic interdependencies 
(Estrela and Brown, 2013). 
The caloric restore is furnished by the 
presence of genes encoding enzymes that 
split vegetable and dietary polysaccharides 
in the microbiota of obese mouse. Admin-
istration of a conventional microbiota to 
germ free mice induced a rapid increase in 
body fat associated with increased hepatic 
triglyceride production related to increased 
activity of two crucial enzymes involved in 
de novo fatty acid synthesis—acetyl coen-
zyme a carboxylase and fatty acid synthe-
tase (Wolf, 2006). The microbiota inhibits 
angiopoietin related protein 4, which sup-
presses lipoprotein lipase, a key regulator of 
fatty acid release from triglyceride rich chy-
lomicrons. Inhibition of angiopoietin relat-
ed protein 4 causes hyper-expression of lip-
oprotein lipase, giving place to an augment-
ed uptake of fatty acids and storage of tri-
glycerides in adipocytes (Wolf, 2006; 
Fleissner et al., 2010) and liver (Fleissner et 
al., 2010). 
Gut microbes have a pivotal role in the 
intra luminal metabolism of bile acids (Ruiz 
et al., 2013). Given that bile acids are fun-
damental for the absorption and emulsifica-
tion of dietary fats and lipid soluble vita-
mins in the small intestine, disorganized 
bile acid physiology could result in an al-
tered energy balance. The role of bile acids 
in maintaining the intestinal barrier function 
and the luminal environment must too be 
called to mind, including their capacity to 
prevent SIBO and bacterial translocation 
(Hagey and Krasowski, 2013; Karatepete 
al., 2010). Additionally, bile acids are in-
volved in energy and lipid metabolism, be-
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ing capable of lowering triglyceride levels, 
for example (Trauner et al., 2010). There-
fore, the microbiota could, because to ef-
fects on bile acid metabolism in the gut lu-
men, influence signalling pathways in-
volved in energy and lipid metabolism. The 
consequences of this involvement include 
the regulation of secondary bile acid me-
tabolism, the inhibition of bile acid synthe-
sis, modifications to lipid peroxidation and 
the storage of fatty acids in the liver (Sayin 
et al. 2013). 
 
Insulin resistance 
Insulin resistance is crucial in the path-
ogenesis of the metabolic syndrome, of 
which NAFLD is considered as the hepatic 
component. Insulin resistance appears to 
have a crucial role in the pathogenesis of 
NAFLD and NASH (Finelli and Tarantino, 
2013a). Besides the suggested role of insu-
lin resistance in the development of steato-
sis, hepatic insulin resistance could promote 
hepatocyte injury and inflammation (Tar-
antino et al., 2009). Gut flora and gut de-
rived endotoxemia are considered main fac-
tors in developing insulin resistance. The 
key link is represented by the lipopolysac-
charide–toll like receptor 4 (TLR4)–
monocyte differentiation antigen CD14 sys-
tem (Penas-Steinhardt et al., 2012; Ma et 
al., 2013; Belforte et al., 2013; Krautbauer 
et al., 2014). Even if this evidence has been 
largely gleaned from animal models, one 
study documented elevated plasma levels of 
lipopolysaccharide among patients with 
obesity and type 2 diabetes mellitus (Ha-
wkesworth et al., 2013). Confirmation of 
these findings and elucidation of the role of 
the microbiota, gut damage and the path-
ways for translocation of bacterial debris 
could open new avenues for prevention and 
treatment of type 2 diabetes, as reported by 
Hawkesworth et al. (2013). Suppression or 
modification of SIBO, by leading to re-
duced proinflammatory cytokine produc-
tion, results in a fall in fasting insulin con-
centrations and decreased insulin resistance 
(Penas-Steinhardt et al., 2012; Rodríguez-
Hernández et al., 2013). Moreover, Car-
valho and Saad (2013) suggested that sev-
eral strategies focusing on modulation of 
the gut microbiota (antibiotics, probiotics, 
and prebiotics) are being experimentally 
employed in metabolic derangement in or-
der to reduce intestinal permeability, in-
crease the production of short chain fatty 
acids and anorectic gut hormones, and pro-
mote insulin sensitivity to counteract the in-
flammatory status and insulin resistance 
found in obese individuals. In another 
study, it hypothesized that ampicillin im-
prove glucose tolerance in mice only if 
treatment is initiated prior to weaning and 
that it disappears when treatment is termi-
nated (Rune et al., 2013). The results sup-
ported the hypothesis that a "window" ex-
ists early in life in which an alteration of the 
gut microbiota affects glucose tolerance as 
well as development of gut immunity and 
that this window may disappear after wean-
ing (Rune et al., 2013). 
The gut microbiota has also been impli-
cated, though in a very different manner, in 
the pathogenesis of type 1 diabetes mellitus 
and is an exceedingly complex microenvi-
ronment that is intimately linked with the 
immune system, including the regulation of 
immune responses (Atkinson and Cher-
vonsky, 2012). Murri et al. (2013) hypothe-
sized that type 1 diabetes in humans could 
also be linked to a specific gut microbiota 
Their aim was to quantify and evaluate the 
difference in the composition of gut micro-
biota between children with type 1 diabetes 
and healthy children and to determine the 
possible relationship of the gut microbiota 
of children with type 1 diabetes with the 
glycemic level This is the first study show-
ing that type 1 diabetes is associated with 
compositional changes in gut microbiota 
The significant differences in the number of 
Bifidobacterium, Lactobacillus and Clos-
tridium and in the Firmicutes to Bacteroide-
tes ratio observed between the two groups 
could be related to the glycemic level in the 
group with diabetes (Murri et al., 2013). 
Moreover, the quantity of bacteria essential 
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to maintain gut integrity was significantly 
lower in the children with diabetes than the 
healthy children. Therefore, Murri et al. 
(2013) suggested that these findings could 
be useful for developing strategies to con-
trol the development of type 1 diabetes by 
modifying the gut microbiota. There is in-
creasing evidence that environmental fac-
tors acting at the intestinal level, with a 
special regard to the diverse bacterial spe-
cies that constitute the microbiota, influ-
ence the course of autoimmune diseases in 
tissues outside the intestine both in humans 
and in preclinical models (Sorini and Fal-
cone, 2013). These observations suggest 
factors in the modern environment promote 
pancreatic islet autoimmunity and destruc-
tion of insulin-producing beta cells (Penno 
et al., 2013). The Environmental Determi-
nants of Islet Autoimmunity (ENDIA) 
Study is investigating candidate environ-
mental exposures and gene-environment in-
teractions that may contribute to the devel-
opment of islet autoimmunity and type 1 
diabetes (Penno et al., 2013). ENDIA eval-
uated the microbiome, nutrition, body-
weight/composition, metabolome-lipidome, 
insulin resistance, innate and adaptive im-
mune function and viral infections (Penno 
et al., 2013). Therefore, Penno et al. (2013) 
suggested that defining gene-environment 
interactions that initiate and/or promote de-
struction of the insulin-producing beta cells 
in early life will inform approaches to pri-
mary prevention of type 1 diabetes. 
 
Altered choline metabolism 
Diets deficient in both methionine and 
choline have been consistently associated 
with the development and progression of 
hepatic steatosis, and have been indicated 
that synergistic effects of protein restriction 
and choline deficiency influence integrated 
metabolism and hepatic pathology in mice 
when nutritional fat content is very high, 
and support the consideration of dietary 
choline content in ketogenic diet studies in 
rodents to limit hepatic mitochondrial dys-
function and fat accumulation (Schugar et 
al., 2013). Decreased choline intake is sig-
nificantly associated with increased fibrosis 
in postmenopausal women with NAFLD 
(Guerrerio et al., 2012). Wattacheril et al. 
(2013) suggest that phospholipid zonation 
may be associated with the presence of an 
intrahepatic proinflammatory phenotype 
and thus have broad implications in the eti-
opathogenesis of.  
Enzymes produced by the gut microbio-
ta catalyze the first step in the conversion of 
dietary choline to dimethylamine and trime-
thylamine (Craciun and Balskus, 2012). 
These metabolites (Rezzi et al., 2007) are 
absorbed through the microvilli and reach 
the liver via the portal vein (Tang et al., 
2013) where trimethylamine is largely 
cleared by hepatic first-pass metabolism be-
fore it enters the systemic circulation. 
Germfree mice do not excrete trimethyla-
mine, supporting an essential role for the 
gut microbiota in the conversion of choline 
to this compound (Bain et al., 2005). Létof-
fé et al. (2014) showed that exposure to 
trimethylamine increases the pH of the 
growth medium of exposed bacteria, result-
ing in modifications in antibiotic uptake 
and transient alteration of antibiotic re-
sistance. This study therefore presents a 
new mechanism by which volatile com-
pounds, during food transformation and 
fermentation, can affect community behav-
ior and structure in physically separated 
bacteria, and it illustrates how airborne 
chemical interactions between bacteria con-
tribute to the development of bacterial 
communities (Létoffé et al., 2014).  
 
Diet and mutations of the gut microbiota 
and host metabolism  
Modification of gut microbiota and/or 
its biochemical ability by specific dietary or 
pharmacological interventions, may con-
veniently affect host metabolism. However, 
in humans to date it is unclear, whether the 
diet-induced effects depend on pre-existent 
gut microbial composition, in interaction 
with the host phenotype, whether oral co-
administration of specific bacterial species 
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together with the dietary substrate is re-
quired, and which mechanisms are in-
volved. Crucially, it is unknown whether 
the observations made in rodents can be ex-
trapolated to humans and ultimately har-
nessed for clinical purposes. In association 
with the tools to modulate the gut microbio-
ta, prebiotics (i.e. ‘non-digestible food in-
gredients that beneficially affect the host by 
selectively stimulating the growth and/or 
activity of one or a limited number of the 
bacteria in the guts’) (Gibson et al., 2004), 
and probiotics (i.e. ‘live microorganisms 
which, when given orally in quantities ade-
quate to allow colonization of the colon, 
confer a health benefit to the host’) (Bertaz-
zoni et al., 2013), are the most important. 
Supplementation with inulin-type fructooli-
gosaccharides (FOS), stimulated growth of 
Bifidobacterium spp. and in some cases 
Lactobacillus spp. in humans (Dewulf et 
al., 2013; Bedani et al., 2013; O'Connell 
Motherway et al., 2013). These groups of 
bacteria, often administrated as probiotics, 
were associated with reduction of intestinal 
endotoxin levels and improvement of mu-
cosal barrier function (Pinzone et al., 2012; 
Rao and Samak, 2013; Fouhy et al., 2013). 
The Bifidobacteria count at baseline is 
strictly related to the increased count after 
treatment, clearly showing that pre-existent 
composition of the gut microbiota is central 
to the response of the intervention (Dewulf 
et al., 2013). Van Bearlen et al. (2009) 
showed that expression profiles of human 
mucosa displayed striking differences in 
modulation of NF-kappaB-dependent path-
ways, notably after consumption of living 
Lactobacillus plantarum bacteria in differ-
ent growth phases. In a randomized, dou-
ble-blind, placebo-controlled trial, inde-
pendently of other lifestyle changes, oli-
gofructose supplementation has the poten-
tial to promote weight loss and improve 
glucose regulation in overweight adults 
(Parnell and Reimer, 2009). Also, Pedersen 
et al. showed that oligofructose dose-
dependently increased peptide YY, de-
creased pancreatic polypeptide and tended 
to decrease ghrelin, but did not significantly 
affect appetite profile, energy intake, glu-
cose, insulin, or glucagon-like peptide 1 
concentrations during appetite study ses-
sions (Pedersen et al., 2013). Pedersen et al. 
concluded that oligo-fructose supplementa-
tion at ≥ 35 g/day increased peptide YY and 
suppressed pancreatic polypeptide and hun-
ger; however, energy intake did not change 
significantly (Pedersen et al., 2013). It has 
demonstrated that a single gene (encoding 
linoleic acid isomerase) expressed in an in-
testinal microbe can influence the fatty acid 
composition of host fat (Rosberg-Cody et 
al., 2011). Fava et al. (2013) suggested a 
new evidence from a large-scale dietary in-
tervention study that high carbohydrate di-
ets, irrespective of glycemic index, can 
modulate human faecal saccharolytic bacte-
ria, including bacteroides and bifidobacteria 
Conversely, high fat diets reduced bacterial 
numbers, and in the high saturated fat diet, 
increased excretion of short-chain fatty ac-
ids (SCFAs), which may suggest a compen-
satory mechanism to eliminate excess die-
tary energy (Fava et al., 2013). In contrast, 
supplementation of non-fermentable carbo-
hydrates such as FOS, which lead to an in-
crease in SFCA formation, had beneficial 
effects on the host metabolic phenotype, in-
cluding increased satiety, body weight and -
fat loss and improvement in insulin sensi-
tivity and glucose tolerance, with several 
mechanisms involved (Fouhyet al., 2013; 
Pourghassem Gargari et al., 2013; Schroed-
er et al., 2013; Whelan, 2013). Of note, bu-
tyrate shows an obvious function of anti-
obesity, and can alleviate the metabolic 
stress, maintain the β-cell function and pro-
tect them from inflammatory response in 
pregnant obese mouse without obvious fe-
tus toxicity (Li et al., 2013). Evidence sup-
porting that dietary inulin alone was effec-
tive to prevent the development of hepatic 
steatosis, ameliorate nutritional effects, and 
alleviate the hepatic change in the expres-
sion of hepatic cytochrome P450 (CYP) 
mRNA, while co-treatment with statin did 
not have additive or synergistic effects and 
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statin may cause adverse effects in rats fed 
the high-fat and high-sucrose diet (Sugatani 
et al., 2012). Reimer et al. (2012) reported 
that novel polysaccharide (NPS) PolyGly-
copleX (PGX) and Sitagliptin improve sev-
eral metabolic outcomes in Zucher diabetic 
fatty rats, but combined, their ability to 
markedly reduce glycemia suggests they 
may be a promising dietary/pharmacologi-
cal co-therapy for type 2 diabetes manage-
ment. Probably, the SCFA-induced physio-
logical effects on colonic functions might 
be attributable to the activation of SCFA 
receptors on epithelial cells in the colon. 
(Tazoe et al., 2008). However, highly vis-
cous, non-fermentable fibers may limit 
weight gain and reduce adiposity and non-
fermentable fibers, regardless of viscosity, 
may promote meal termination (Schroeder 
et al., 2013). Another, fermentable indigest-
ible carbohydrate increases the number of 
free fatty acid receptor 2 -positive L-cells in 
the proximal colon (Schroeder et al., 2013). 
Free fatty acid receptor 2 activation by 
SCFAs might be an important trigger for 
produce and release GLP-1 by enteroendo-
crine L-cells in the lower intestine 
(Schroeder et al., 2013). Also, FOS in mice 
increased the number of intestinal 
bifidobacteria and reduced the impact of 
high-fat diet-induced endotoxaemia and in-
flammation (Pourghassem Gargari et al., 
2013; Schroeder et al., 2013). Several stud-
ies in humans already support interest in 
FOS in the control of satiety, triglyceridem-
ia, or steatohepatitis (Delzenne et la., 2007). 
Moran-Ramos et al. (2012) suggested that 
the potential for diet interventions as a 
promising strategy for modulating gut hor-
mone responses to food ingestion and, ulti-
mately, preventing or treating metabolic 
diseases is being emphasized considering 
that these diseases are currently a public 
health burden. The link with gut peptides 
production in humans remains to be proven. 
Therefore, we hypothesize that the ef-
fects of dietary factors on gut microbiota 
and host metabolism, particularly in hu-
mans, are as yet widely unknown. These 
may depend on both the dietary interven-
tion and the pre-existent gut microbial 
composition, in relation to the host pheno-
type. 
 
GUT MICROFLORA'S COMPOSI-
TION AND NON-DIETARY FACTORS  
Gut microflora composition in an indi-
vidual’s colon likely is influenced by a 
combination of dietary habits and other 
host- and non-host-associated factors. For 
example, the exposure of individuals to mi-
crobes capable of establishing residence in 
the gut might depend on geographic loca-
tion, with large differences expected be-
tween individuals living in areas with dif-
ferent levels of drinking water purity and 
food quality; different levels of hygiene; or 
with different climates. Other factors that 
may contribute to the progression of the in-
testinal microflora include initial coloniza-
tion after birth, driven by the presence of 
selective nutrients in the mother’s milk; 
host genetic factors that influence the secre-
tion of substances that facilitate selection 
for specific bacteria; immune control that 
favors growth of some groups of bacteria; 
and random chance that results in a coloni-
zation cascade. Another factor that can alter 
an established microflora is antibiotic 
treatment. Antibiotics interfere with the ex-
isting microflora by selecting in contrast to 
vulnerable bacteria and, even after treat-
ment, the re-establishment of the full com-
plexity of the microflora might result in a 
changed composition. Buccigrossi et al. 
(2013) sustained that a relationship exists 
between eubiosis and functions and con-
versely between dysbiosis and dysfunctions 
or even diseases. Abnormalities in micro-
flora composition may trigger or contribute 
to specific diseases. This raises the hypoth-
esis to target microflora in order to restore 
eubiosis through the use of antibiotics, pro-
biotics or nutrients (Buccigrossi et al., 
2013).  
Differences between physical activity 
levels might too change gut microflora 
composition. Even if moderate exercise has 
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not been shown to reduce transit time 
through the intestinal tract, elevated activity 
levels might change other aspects of intesti-
nal physiology and, in this manner, the con-
ditions for microbial growth (Kim, 2012; 
Cho et al., 2013). Valdés-Ramos et al. 
(2010) suggest that high-fat diets combined 
with exercise are able to induce an increase 
in CD3+ lymphocytes due to increased 
CD8+ cells and a decrease in B-cells and 
the authors concluded that explanations and 
consequences of the effects of diet and ex-
ercise on the gut mucosal immunity are still 
being explored (Valdés-Ramos et al., 
2010). Another, it observed substantial tax-
onomic changes in the microbiome, chang-
es in copies of key genes involved in the 
metabolism of carbohydrates to short-chain 
fatty acids, increases in colonic short-chain 
fatty acid levels, and alterations in the regu-
lation of hepatic metabolism of lipids and 
cholesterol (Cho et al., 2012). Therefore, 
Cho et al. (2012) demonstrated the altera-
tion of early-life murine metabolic homeo-
stasis through antibiotic manipulation. For 
these findings, we hypothesized that as-yet-
undiscovered factors, or random chance, 
too is partly responsible for the establish-
ment and maintenance of the intestinal mi-
crobiota. 
In a human dietary intervention study 
reporting beneficial effects of green and 
black tea drinking on serum lipids (Hartley 
et al., 2013), Henning et al. (2013) observed 
that the consumption of both, green tea and 
black tea, was associated with a significant 
increase in urinary and serum phenolic ac-
ids. Tea polyphenols are metabolized by the 
colonic microflora yielding phenolic me-
tabolites, which may contribute to the 
health benefits of tea (Henning et al., 2013). 
We hypothesize that, at least for short study 
intervals, the constituted microflora had an 
overwhelming effect on the flora’s final 
composition, thus indicating the need for a 
longer follow-up in dietary studies. 
Due to substrate availability, water con-
tent, and other physiologic conditions, the 
highest microbial activity is found in the 
proximal colon (Tannock, 2002; Macfar-
lane and Macfarlane, 2012). In that regard, 
although the microflora’s composition ap-
pears to be affected by factors that are pri-
marily associated with diet (i.e., changes in 
substrate availability, pH, and reduction po-
tential), it might also be influenced by ge-
netic and other as-yet-undiscovered factors.  
 
SMALL INTESTINAL BACTERIAL 
OVERGROWTH (SIBO) 
The progression of simple steatosis to 
steatohepatitis is essentially an inflamma-
tory rather than a metabolic process; risk 
factors associated with this change include 
obesity and a high BMI (Tarantino et al., 
2010; Greene et al., 2014; Alkhouri et al., 
2014a). Several lines of evidence, detailed 
below, have suggested that SIBO might 
play an important part in progression of 
NAFLD to NASH. Intestinal failure and to-
tal parenteral nutrition (TPN) are associated 
with NAFLD and progression to NASH 
(Corbin and Zeisel, 2012; Rollins et al., 
2013). SIBO, related probably to intestinal 
hypomotility as well as other factors, such 
as suppressed secretion of gastric acid and 
intestinal enzymes and reduced bile flow, 
has been considered as a causative factor 
(Corbin and Zeisel, 2012; Rollins et al., 
2013).  
The use of TPN in the treatment of crit-
ically ill patients has been the subject of 
debate because it has been associated with 
alterations in intestinal homeostasis (Hodin 
et al., 2012). Important factors in maintain-
ing intestinal homeostasis are the intestinal 
microbiota and Paneth cells, which exist in 
a mutually amendable relationship. Hodin 
et al. (2012) showed a shift in intestinal mi-
crobiota in TPN-fed rats that correlated 
with changes in Paneth cell lysozyme ex-
pression. Further studies that include inter-
ventions with microbiota or nutrients that 
modulate them may yield information on 
the involvement of the microbiota and Pan-
eth cells in TPN-associated intestinal com-
promise (Hodin et al., 2012). However, the 
contribution of the intestinal microbiome to 
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liver disease goes beyond simple transloca-
tion of bacterial products that promote he-
patic injury and inflammation (Schnabl and 
Brenner, 2014). Microbial metabolites pro-
duced in a dysbiotic intestinal environment 
and host factors are equally important in the 
pathogenesis of liver disease (Schnabl and 
Brenner, 2014). Therefore, we hypothesize 
that the combination of liver insult and dis-
ruptions in intestinal homeostasis contribute 
to liver disease. 
The increased abundance of alcohol-
producing bacteria in NASH microbiomes, 
elevated blood-ethanol concentration in 
NASH patients, and the well-established 
role of alcohol metabolism in oxidative 
stress and, thus, liver inflammation suggest 
a role for alcohol-producing microbiota in 
the pathogenesis of NASH (Zhu et al., 
2013). Zhu et al. (2013) postulated that the 
distinct composition of the gut microbiota 
among NASH, obese, and healthy controls 
could offer a target for intervention or a 
marker for disease. In addition, several ex-
perimental studies and clinical trials re-
vealed promising effects of probiotics in 
improving NAFLD; however given the lim-
ited experience in this field, generalization 
of probiotics as treatment of NAFLD needs 
substantiation through more trials with a 
larger sample sizes and with longer-term 
follow up (Kelishadi et al., 2013).  
Younossi et al. (2014) suggested that 
NASH associated with metabolic syndrome 
can progress advanced fibrosis and cirrho-
sis. Weight loss and lifestyle modification 
have been shown to improve NASH. Other 
medications used for weight loss and meta-
bolic syndrome have been evaluated, such 
as orlistat, metformin and thiazolidinedi-
ones, as reported by Younossi et al. 
(Younossi et al., 2014). Alternative regi-
mens using ursodeoxycholic acid, statins 
and probiotics as well as bariatric surgery 
have been evaluated, but have not been rec-
ommended as first-line treatment for NASH 
(Younossi et al., 2014). Vitamin E for 
NASH patients without diabetes seems to 
be promising (Younossi et al., 2014). The 
lack of effective treatment for NASH sug-
gests the heterogeneity of patients present-
ing with the NASH phenotype (Younossi et 
al., 2014). The best treatment strategy for 
these patients may be to identify their path-
ogenic target and develop personalised 
treatment protocols (Younossi et al., 2014). 
Shanab et al. showed that NASH patients 
have a higher prevalence of SIBO which is 
associated with enhanced expression of 
TLR-4 and release of IL-8 (Shanab et al., 
2011). SIBO may have an important role in 
NASH through interactions with TLR-4 and 
induction of the pro-inflammatory cytokine, 
IL-8 (Shanab et al., 2011). It showed that 
probiotic combination with metformin im-
proves liver aminotransferases better than 
metformin alone in patients with NASH 
(Shavakhi et al., 2013). 
Nevertheless, NASH recurs immediate-
ly after liver transplantation unless the jeju-
noileal bypass is removed (Charlton, 2013). 
However, Wu et al. (2008) suggested that 
SIBO may decrease small intestinal move-
ment in NASH rats. Another, SIBO may be 
an important pathogenesis of NASH and 
treatment with cidomycin by mouth can al-
leviate the severity of NASH (Wu et al., 
2008). In addition, gut flora and bacterial 
translocation play important roles in the 
pathogenesis of chronic liver disease, in-
cluding cirrhosis and its complications 
(Ilan, 2012). Intestinal bacterial overgrowth 
and increased bacterial translocation of gut 
flora from the intestinal lumen predispose 
patients to bacterial infections, major com-
plications and also play a role in the patho-
genesis of chronic liver disorders (Ilan, 
2012). A better understanding of the cell-
specific recognition and intracellular signal-
ing events involved in sensing gut-derived 
microbes will help in the development of 
means to achieve an optimal balance in the 
gut-liver axis and ameliorate liver diseases 
(Ilan, 2012). These may suggest new targets 
for potential therapeutic interventions for 
the treatment of NASH (Ilan, 2012). Both 
obesity and diabetes, key factors in NASH 
progression, are also associated with intes-
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tinal dysmotility (Stenkamp-Strahm et al., 
2013), which could potentially lead to 
SIBO (Bures et al., 2010; Jacobs et al., 
2013; Mushref and Srinivasan, 2013). 
Ghrelin, a gastric hormone that regulates 
food intake, also exerts prokinetic effects 
(Strasser, 2012; Queipo-Ortuño et al., 
2013). Patients with NASH show low 
ghrelin levels (Gonciarz et al., 2013; Ma-
chado et al., 2012), which could lead to re-
duced gut motility and encourage retro-
grade colonization of the small intestine by 
colonic bacteria and, probably, the progres-
sion of SIBO.  
Rana et al. (2014) showed that increase 
in cytokines and decrease in anti-oxidants 
in ulcerative colitis patients would have re-
sulted in oxidative stress causing delayed 
gastrointestinal motility leading to SIBO.  
Miele et al. (2009) suggested that 
NAFLD in humans is associated with in-
creased gut permeability and that this ab-
normality is related to the increased preva-
lence of SIBO in these patients. The in-
creased permeability appears to be caused 
by disruption of intercellular tight junctions 
in the intestine, and it may play an im-
portant role in the pathogenesis of hepatic 
fat deposition (Miele et al., 2009). Disrup-
tion of tight junctions between intestinal ep-
ithelial cells by bacterial toxins or other in-
flammatory mediators leads to translocation 
of intraluminal contents (and, notably, bac-
terial endotoxins) into the systemic circula-
tion. 
Sachdev and Pimentel (2013) suggested 
that quantitative culture of small bowel 
contents and a variety of indirect tests have 
been used over the years in an attempt to 
facilitate the diagnosis of SIBO. The indi-
rect tests include breath tests and biochemi-
cal tests based on bacterial metabolism of a 
variety of substrates. Infact, Rana and 
Bhardwaj (2008) suggested that SIBO can 
be diagnosed by: 1) culture of jejunum aspi-
rate for bacterial counts, 2) 14C-D-xylose 
breath testing, 3) non-invasive hydrogen 
breath testing using glucose or lactulose or 
4) 14C-glycocholic acid breath testing. Ac-
tually, there is no single valid test for SIBO, 
and the accuracy of all current tests remains 
limited due to the failure of culture to be a 
gold standard and the lack of standardiza-
tion of the normal bowel flora in the small 
intestine (Sachdev and Pimentel, 2013). In-
terestingly, in morbidly obese patients, bac-
terial overgrowth prevalence is higher than 
in healthy subjects and is associated with 
severe hepatic steatosis (Sabaté et al., 
2008). Therefore, the ideal approach to treat 
SIBO is to treat the underlying disease, 
eradicate overgrowth, and address nutri-
tional deficiencies that may be associated 
with the development of SIBO (Sachdev 
and Pimentel, 2013).  
 
THE GUT MICROBIOTA AND  
HEPATOTOXIC EFFECTS 
The gut microflora has been identified 
to have possible hepatotoxic effects for 
numerous years. Indeed, the intestinal mi-
crobiota produces a number of probably 
hepatotoxic compounds, such as ammonia, 
ethanol, acetaldehyde, phenols and benzo-
diazepines, which must be consequently 
metabolized in the liver. Bacterial endotox-
ins reaching the liver through the portal cir-
culation activate the hepatic Kupffer cells 
and stimulate their production of nitric ox-
ide and cytokines. Altered intestinal perme-
ability might ease the delivery of these 
hepatotoxic factors to the liver. Bacterial 
endotoxin, such as lipopolysaccharide 
(LPS), plays an important role in the patho-
genesis of NAFLD (Fukunishi et al., 2014). 
In fact, Fukunishi et al. (2014) suggest that 
LPS may accelerate the progression of he-
patic steatosis. In association with the nu-
merous bacterial products, lipopolysaccha-
ride and ethanol appear to be the most im-
portant factors in NAFLD pathogenesis.  
 
Lipopolysaccharide 
Lipopolysaccharide (LPS), the active 
component of endotoxin, binds to lipopoly-
saccharide binding protein (LBP), CD14, 
TLR4 and lymphocyte antigen 96, among 
other receptors. Roh and Seki (2013) sug-
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gested that gut microflora-derived bacterial 
products (i.e. LPS) and endogenous sub-
stances (i.e. high-mobility group protein B1 
[HMGB1], free fatty acids) released from 
damaged cells activate hepatic TLRs that 
contribute to the development of alcoholic 
and NASH and liver fibrosis. The crucial 
role of TLR4, a receptor for LPS, has been 
implicated in the development of alcoholic 
steatohepatitis, NASH, liver fibrosis, and 
hepatocellular carcinoma (Roh and Seki, 
2013).  
In fact, LPS binds to LBP and the LBP–
LPS complex binds to CD14 on Kupffer 
cells. Then TLR associates with CD14 on 
the cell surface, triggering an essential in-
tracellular inflammatory cascade, including 
stress-activated and mitogen-activated pro-
tein kinases, c-Jun N-terminal kinase 
(JNK), p38 and the nuclear factor κB 
(NFκB) pathway. Activation of Inhibitor of 
NFκB kinase β subunit kinase (IKK) leads 
to the phosphorylation and complete degra-
dation of IKK-β, an NFκB inhibitor. NFκB 
translocates to the nucleus, where it binds 
to the promoter region of a number of target 
genes involved in the inflammatory path-
way, such as TNF and IL-1β. 
 
Metabolic effects 
Endogenous lipopolysaccharide is a 
complex of polysaccharide components and 
lipids. The lipid moiety, termed lipid a, is 
thought to be relevant to the induction of 
metabolic effects. In mice, lipopolysaccha-
ride infusion resulted in increased fasting 
levels of glucose and insulin, as well as 
weight gain; the effects of this treatment on 
total body fat, steatosis and adipose tissue 
were similar to those induced by a high-fat 
diet. In parallel with these changes, the 
numbers of macrophages in adipose tissue 
and levels of inflammatory markers and he-
patic triglycerides increased. In addition, 
insulin sensitivity in the liver (but not in 
other body tissues) was modified in lipo-
polysaccharide infused mice. Visceral and 
subcutaneous fat deposition was likewise 
increased in both the high-fat diet and lipo-
polysaccharide infused groups of animals 
(Krautbauer et al., 2014).  
Moreover, fat ingestion elevates the ef-
fectiveness of translocation of intestinal 
bacterial LPS (Lee, 2013). A high-fat diet 
produces a considerable quantity of lipopro-
tein containing chylomicrons, which pro-
mote LPS translocation to extraintestinal 
tissues (Demignot et al., 2014). For indi-
viduals on a high-fat diet, therefore, a pri-
mary factor in the induction of metabolic 
diseases could be activation of an inflam-
matory cascade, induced by lipopolysaccha-
ride binding to the complex of lymphocyte 
antigen 96, CD14 and TRL4 on the surface 
of immune cells (Racioppi et al., 2012). 
Another, Racioppi et al. (2012) sustained 
that calcium/calmodulin-dependent kinase 
kinase 2 (CaMKK2) plays a key role in 
regulating food intake and energy expendi-
ture at least in part by its actions in hypo-
thalamic neurons. 
Lipopolysaccharide can stimulate mon-
ocytes and macrophages to produce the pro-
inflammatory cytokines TNF, IL1 and IL6 
(Li et al., 2014). Accordingly, several stud-
ies have reported high levels of proinflam-
matory cytokines, notably TNF, in obese 
individuals (Miele et al., 2009; Zhong et al., 
2013; Gonzalez-Quintela et al., 2013; 
Zunino et al., 2013). TNF can induce insu-
lin resistance by dual effects on insulin sen-
sitive tissues, and this cytokine rapidly 
abolishes insulin receptor signalling in adi-
pocytes, hepatocytes and skeletal muscle 
cells in tissue culture (Lorenzo et al., 2008; 
Di Renzo et al., 2013; Carstensen et al., 
2014). Furthermore, TNF-α in male Wistar 
rats models showed improved glucose and 
insulin homeostasis (Ahmed et al., 2014). 
CD14, which acts as a lipopolysaccharide 
co-receptor along with lymphocyte antigen 
96 and TLR4, might be the main molecule 
mediating insulin resistance and, hence, the 
occurrence of obesity and diabetes. Obese 
rodents lacking CD14 were protected from 
obesity, diabetes, the development of stea-
tosis and visceral fat mass accumulation af-
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ter lipopolysaccharide administration 
(Krautbauer et al., 2014).  
 
Proinflammatory effects 
In a murine model with NAFLD, hepat-
ic fat accumulation induces the liver to fur-
ther grave injury by hepatotoxins and/or in-
fectious agents, leading to NASH and the 
eventual progression of cirrhosis (Vansaun 
et al., 2013). Shen et al. (2005) reported 
that addition of leptin to normal rats in-
creased LPS-induced hepatic TNF-alpha 
production in vivo and leptin receptor-
deficient Zucker rats showed reduced he-
patic TNF-alpha production on addition of 
LPS in vivo. These findings indicate that 
P38 and JNK pathways are involved in the 
signal transduction of leptin enhancement 
of LPS-induced TNF-alpha production 
(Shen et al., 2005). Furthermore, Imajo et 
al. demonstrated that up-regulation of 
CD14 by leptin-mediated signaling is criti-
cal to hyperreactivity against endotoxin 
during NASH progression (Imajo et al., 
2012). Up-regulation of CD14 in Kupffer 
cells and hyperreactivity against low-dose 
LPS were observed in high-fat diet (HFD)-
induced steatosis mice, but not chow-fed-
control mice (Imajo et al., 2012). Hyperre-
sponsivity against low-dose LPS led to ac-
celerated NASH progression, including liv-
er inflammation and fibrosis. Administering 
leptin in chow-fed mice caused increased 
hepatic expression of CD14 via STAT3 
signaling, resulting in hyperreactivity 
against low-dose LPS without steatosis. In 
contrast, a marked decrease in hepatic 
CD14 expression was observed in leptin-
deficient ob/ob mice, despite severe steato-
sis (Imajo et al., 2012). 
Lipopolysaccharide induced production 
of cytokines is initiated by binding of lipo-
polysaccharide to LBP, followed by the at-
tachment of this complex to CD14 on Kup-
ffer cells. TLR4 associates with CD14 on 
the cell surface to initiate lipopolysaccha-
ride induced signal transduction - notably, 
activation of nuclear factor Κb (NFκB) and 
the subsequent production of proinflamma-
tory cytokines, such as TNF and cyclooxy-
genase 2 (Imajo et al., 2012; Ling et al., 
2014). Activation of TLR4 by lipopolysac-
charide triggers an essential intracellular in-
flammatory cascade, including stress-
activated and mitogen-activated protein ki-
nases, c-Jun-N-terminal kinase, p38 and the 
nFκB pathway. Activation of inhibitor of 
NFκB kinase subunit β (IKKβ) kinase leads 
to the phosphorylation and complete degra-
dation of IKKβ, an NFκB inhibitor. Re-
moval of IKKβ allows NFκB to translocate 
to the nucleus, where it binds to the pro-
moter region of a number of target genes 
involved in the inflammatory pathway, such 
as TNF and IL-1β (Huang and Hung, 2013). 
Thus, NFκB might be a key factor in the 
induction of pro-inflammatory cytokines. 
Evidence, mostly from animal models, 
shows that this pathway is activated in the 
presence of NASH. Ruiz et al. (2007) 
showed that NAFLD patients have elevated 
plasma levels of LPS-binding and they are 
further increased in patients with NASH. 
This increase is related to a rise in TNF-
alpha gene expression in the hepatic tissue 
which supports a role for endotoxemia in 
the development of steatohepatitis in obese 
patients, as reported by Ruiz et al. (2007). 
Stanković et al. (2014) suggested that 
methionine-choline deficient (MCD) diet 
duration necessary for development of 
NAFLD and the dynamic of lipid profile 
and fatty acids are not completely estab-
lished. Therefore, in their study examined 
dynamics and association between liver free 
fatty acids, serum lipid profile and liver 
morphological changes on MCD diet-
induced NAFLD in mice. Stanković et al. 
(2014) concluded that supplementation with 
n-3 polyunsaturated acid, especially in the 
initial stage of fatty liver disease, may po-
tentially have preventive effects and allevi-
ate development of NAFLD/NASH and 
may also potentially reduce cardiovascular 
risk by moderating dyslipidemia (Stanković 
et al., 2014). 
Some studies have suggested that bacte-
rial overgrowth and endotoxemia along 
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with its receptor, TLR-4, play a role in the 
pathogenesis of NAFLD. Kiziltas et al. 
(2014) reported that as the first-time-in-
humans controlled study related to investi-
gation of TLR4 gene polymorphism in 
NAFLD, their findings contribute to the 
available data that TLR-4 signaling is piv-
otal for the pathogenesis of NASH and in-
dicate that the TLR4 codon 299 heterozy-
gous gene mutation (Asp299Gly) in hu-
mans may have a preventive role against 
the genesis of NAFLD. 
Inflammatory cytokines, such as TNF-α 
and IFN-γ, induce, as reported by Kawara-
tani et al. (2013), liver injury in the rat 
model of NASH. Another, hepatoprotective 
cytokines, such as IL-6, and anti-inflam-
matory cytokines, such as IL-10, are also 
associated with NASH (Kawaratani et al., 
2013). Besides, IL-6 improves NASH via 
activation of the signal transducer and acti-
vator of transcription 3 (STAT3) and the 
subsequent induction of a variety of hepa-
toprotective genes in hepatocytes (Kawara-
tani et al., 2013). IL-10 inhibits alcoholic 
liver inflammation via activation of STAT3 
in Kupffer cells and the subsequent inhibi-
tion of liver inflammation (Kawaratani et 
al., 2013). Alcohol consumption promotes 
liver inflammation by increasing transloca-
tion of gut-derived endotoxins to the portal 
circulation and activating Kupffer cells 
through the LPS/TLR 4 pathways. Another, 
oxidative stress and microflora products are 
also associated with NASH (Kawaratani et 
al., 2013). Therefore, interactions between 
pro- and anti-inflammatory cytokines and 
other cytokines and chemokines are likely 
to play important roles in the development 
of NASH (Kawaratani et al., 2013).  
Hepatic stellate cells (HSCs) could play 
a main role in generating the liver inflam-
matory cascade associated with endotoxe-
mia (Harvey et al., 2013; Stewart et al., 
2014).  
HSCs are the major cell type involved 
in liver fibrosis. Lipopolysaccharide (LPS)-
mediated signaling through TLR4 in HSCs 
has been identified as a key event in liver 
fibrosis, and as the molecular link between 
inflammation and liver fibrosis (Zhao et al., 
2014). Therefore, Zhao et al. investigated 
the effects of caffeic acid phenethyl ester 
(CAPE), one of the main medicinal compo-
nents of propolis, on the pro-inflammatory 
and fibrogenic phenotypes of LPS-stimu-
lated HSCs (Zhao et al., 2014). HSCs from 
rats were isolated and cultured in Dulbec-
co's modified Eagle's medium (DMEM) 
(Zhao et al., 2014). Following treatment 
with LPS, HSCs showed a strong pro-in-
flammatory phenotype with an up regula-
tion of pro-inflammatory mediators, and a 
fibrogenic phenotype with enhanced colla-
gen synthesis, mediated by transforming 
growth factor-β1 (TGF-β1) (Zhao et al., 
2014). CAPE significantly and dose-
dependently reduced LPS-induced nitrite 
production, as well as the transcription and 
protein synthesis of monocyte chemoat-
tractant protein-1 (MCP-1), interleukin-6 
(IL-6) and inducible nitric oxide synthase 
(iNOS), as determined by quantitative re-
verse transcription-polymerase chain reac-
tion (qRT-PCR), western blotting and en-
zyme-linked immunosorbent assays (ELI-
SA) (Zhao et al., 2014). CAPE further re-
duced the TGF-β1-induced transcription 
and translation (protein synthesis) of the 
gene coding for collagen type I α1 
(col1A1), in LPS-stimulated HSCs (Zhao et 
al., 2014). Following LPS stimulation, the 
phosphorylation of the nuclear factor-κB 
(NF-κB) inhibitor IκBα and consequently, 
the nuclear translocation of NF-κB, were 
markedly increased in the HSCs, and these 
changes were reversed by pre-treatment 
with CAPE (Zhao et al., 2014). Zhao et al. 
(2014) concluded that CAPE attenuates the 
pro-inflammatory phenotype of LPS-
stimulated HSCs, as well as the LPS-
induced sensitization of HSCs to fibrogenic 
cytokines by inhibiting NF-κB signaling. 
These results provide new insight into the 
treatment of hepatic fibrosis through regula-
tion of the TLR4 signaling pathway (Zhao 
et al., 2014). Thus, HSCs play an important 
role both in endotoxin-induced acute 
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hepatocyte injury, with TNF-α and endo-
thelin-1 as important mediators of these ef-
fects (Stewart et al., 2014).  
 
Ethanol 
Acetaldehyde and acetate are two major 
metabolites of ethanol. Ethanol can increase 
production of acetate via inhibition of the 
tricarboxylic acid cycle. In turn, acetate is a 
substrate for fatty acid synthesis (Sato et al., 
2014). Acetaldehyde and its metabolites 
might lead to the formation of reactive oxy-
gen species, which increase oxidative stress 
and, ultimately, induce liver injury (Tar-
antino et al., 2014).  
Ye et al. (2013) investigated the role of 
Cytochrome P4502E1 in sensitizing Kup-
ffer cells to LPS-mediated inflammation af-
ter ethanol induction. As reported by Ye et 
al. (2013), in cultured Kupffer cell, using 
chlormethiazole as inhibitor, ethanol-indu-
ced CYP2E1 overexpression was proved to 
contribute to the sensitization of Kupffer 
cells to LPS stimuli, with amplification of 
ROS production and activation of NF-κB, 
resulting in increased TNF-α production. 
Alkhouri et al. (2014b) showed that ex-
haled breath analysis is a promising non in-
vasive method to detect fatty liver in chil-
dren. Therefore, isoprene, acetone, trime-
thylamine, acetaldehyde, and pentane are 
novel biomarkers that may help to gain in-
sight into pathophysiological processes 
leading to the development of NAFLD 
(Alkhouri et al., 2014b). Treating these an-
imals with probiotics to modify the gut mi-
crobiota improved NAFLD histology and 
decreased serum levels of liver enzymes 
(Penas-Steinhardt et al., 2012). Zhu et al. 
(2013) showed that the increased abun-
dance of alcohol-producing bacteria in 
NASH microbiomes, elevated blood-etha-
nol concentration in NASH patients, and 
the well-established role of alcohol metabo-
lism in oxidative stress and, consequently, 
liver inflammation suggest a role for alco-
hol-producing microbiota in the pathogene-
sis of NASH. Ethanol is partly responsible 
for the physiological and morphological 
modifications in the intestinal barrier asso-
ciated with SIBO, and thus enhances the 
passage of endotoxins from the gut lumen 
into the portal blood (Cariello et al., 2010). 
Nair et al. (2001) suggested that higher 
breath ethanol concentrations are observed 
in obese subjects than in leaner ones (Nair 
et al., 2001). It is possible that intestinally 
derived ethanol may contribute to the path-
ogenesis of NASH. 
 
PROBIOTICS AND PREBIOTICS 
In vitro studies, as reported by Druart et 
al. (2014), have suggested that isolated gut 
bacteria are able to metabolize PUFA into 
CLA (conjugated linoleic acids) and CLnA 
(conjugated linolenic acids). However, the 
bioavailability of fatty acid metabolites 
produced in vivo by the gut microbes re-
mains to be studied. Druart et al. (2014) 
concluded that the accumulation of the 
main metabolites (CLA cis-9,trans-11-18:2 
and CLnA cis-9, trans-11, cis-15-18:3) in 
the caecal tissue was not associated with 
their increase in the plasma, therefore sug-
gesting that, if endogenously produced 
CLA and CLnA have any biological role in 
host metabolism regulation, their effect 
would be confined at the intestinal level, 
where the microbiota is abundant (Druart et 
al., 2014). The effects of administering 
prebiotics have illustrated the ability of the 
gut microbiota to affect host metabolism by 
both reducing energy intake and protecting 
the host from weight gain; the latter effect 
might be mediated by altered release of gut 
peptides involved in appetite and weight 
control (Pyra et al., 2012; Koleva et al., 
2012; Everard et al., 2013; Bomhof et al., 
2014; Dewulf et al., 2013; Closa-
Monasterolo et al., 2013).  
Rauch and Lynch (2012) suggested that 
modulating microbial exposure through 
probiotic supplementation represents a 
long-held strategy towards ameliorating 
disease via intestinal microbial community 
restructuring. Therefore, this field has expe-
rienced somewhat of resurgence over the 
past few years, primarily due to the expo-
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nential increase in human microbiome stud-
ies and a growing appreciation of our de-
pendence on resident microbiota to modu-
late human health (Rauch and Lynch, 
2012). Wang et al. (2013b) reported that the 
therapeutic effects of probiotic treatment in 
alcoholic liver disease have been studied in 
both patients and experimental animal 
models. Although the precise mechanisms 
of the pathogenesis of alcoholic liver dis-
ease are not fully understood, gut-derived 
endotoxin has been postulated to play a 
crucial role in hepatic inflammation (Wang 
et al., 2013b). Previous studies have de-
monstrated that probiotic therapy reduces 
circulating endotoxin derived from intesti-
nal gram-negative bacteria in alcoholic liver 
disease. Wang et al. (2013b) concluded that 
probiotic Lactobacillus rhamnosus GG 
(LGG) treatment reduced alcohol-induced 
hepatic inflammation by attenuation of 
TNFα production via inhibition of TLR4- 
and TLR5-mediated endotoxin activation 
(Wang et al., 2013b). Another, early low 
volume oral synbiotic/prebiotic supple-
mented enteral stimulation of the gut seems 
to be a potentially valuable complement to 
the routine treatment protocol of severe 
acute pancreatitis, as reported by Plaudis et 
al. (Plaudis et al., 2012). Therefore, the eth-
anol-induced pathogenic changes in the mi-
crobiome and the liver were prevented by 
LGG supplementation (Bull-Otterson et al., 
2013). Overall, significant alterations in the 
gut microbiome over time occur in response 
to chronic alcohol exposure and correspond 
to increases in intestinal barrier dysfunction 
and development of alcoholic liver disease 
(Bull-Otterson et al., 2013). Furthermore, 
the altered bacterial communities of the gut 
may serve as significant therapeutic target 
for the prevention/treatment of chronic al-
cohol intake induced intestinal barrier dys-
function and liver disease (Bull-Otterson et 
al., 2013). Dewulf et al showed that inulin-
type fructans, which promote gut fermenta-
tion, paradoxically counteract GPR43 (a G 
protein-coupled receptor, potential link be-
tween gut fermentation processes and white 
adipose tissue development) overexpression 
induced in the adipose tissue by an high-fat 
diet, a phenomenon that correlates with a 
beneficial effect on adiposity and with po-
tential decrease in PPARγ-activated pro-
cesses (Dewulf et al., 2011). 
Probiotics alter the intestinal microbiota 
with non-urease-producing organisms that 
reduce production of ammonia (Lunia et al., 
2013). In a prospective, randomized con-
trolled trial conducted by Lunia et al., pro-
biotics were found to be effective in pre-
venting hepatic encephalopathy in patients 
with cirrhosis (Lunia et al., 2013). 
Lactulose promotes equol production 
and changes the microbial community dur-
ing in vitro fermentation of daidzein by fe-
cal inocula of sows (Zheng et al., 2014). 
Equol has higher biological effects than 
other isoflavones. However, only about 30-
50 % of humans possess a microbiota capa-
ble of producing equol from dietary daidze-
in. In recent years, interest has grown in di-
etary applications to improve equol produc-
tion in human and other animals. Zheng et 
al. (2014) showed that lactulose was used 
as a potential equol-promoting prebiotic in 
vitro. The effect of lactulose on transfor-
mation of daidzein into equol by sows' fecal 
microbiota was investigated (Zheng et al., 
2014). Results showed that lactulose treat-
ment improved bacteria growth parameters, 
changing the kinetics of fermentation in 
vitro. Lactulose significantly increased total 
gas production (Zheng et al., 2014). Fur-
thermore, lactulose altered the microflora 
composition, increased equol production 
associated with a reduction in the popula-
tion of methanogen and increased the sul-
fate-reducing bacteria population during 24 
h of incubation. Zheng et al. (2014) report-
ed for the first time that in a certain condi-
tion (sealing or high pressure), via a dihy-
drodaidzein pathway equol might be able to 
reform to daidzein by further metabolism 
using lactulose as a substrate. Zheng et al. 
(2014), in this study, proposed that "hydro-
gen-producing prebiotic" might be a novel 
way to promote equol production in vivo or 
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in vitro (Zheng et al., 2014). Finally, exper-
imental models, as reported by Imajo et al. 
(2014), have highlighted several mecha-
nisms connecting microbiota to the devel-
opment of liver dysfunction in NASH such 
as increased energy harvesting from the di-
et, small intestine bacterial overgrowth, 
modulation of the intestinal barrier by glu-
cagon-like peptide-2 secretions, activation 
of innate immunity through the lipopoly-
saccharide-CD14 axis caused by obesity-
induced leptin, periodontitis, and sterile in-
flammation. The manipulation of microbio-
ta through probiotics, prebiotics, antibiotics, 
and periodontitis treatment yields encourag-
ing results for the treatment of obesity, dia-
betes, and NASH, but data in humans is 
scarce (Imajo et al., 2014). 
 
Metabolic effects 
Tomaro-Duchesneau et al. (2014) indi-
cated that administration of the ferulic acid 
(a phenolic acid found in foods normally 
consumed by humans that has demonstrated 
antioxidant activity, cholesterol-lowering 
capabilities, and anti-tumorigenic proper-
ties) producing L. fermentum NCIMB 5221 
has the potential to reduce insulin re-
sistance, hyperinsulinemia, hypercholester-
olemia, and other markers involved in the 
pathogenesis of metabolic syndrome. Cer-
tain probiotics, including Lactobacillus and 
Bifidobacterium spp., have the capacity to 
synthesize bile salt hydrolase (Ruiz et al., 
2013), a key enzyme in the deconjugation 
of bile acids. Deconjugated bile acids are 
less effective in micelle formation and the 
emulsification of ingested lipids than con-
jugated bile acids and, therefore, reduce the 
efficiency of fat absorption (Cirin et al., 
2011; Yokota et al., 2012; Hagey and Kra-
sowski, 2013; Cherrington et al., 2013; 
Chen et al., 2013). Through cholesterol-
lowering effects, Lactobacillus and Bifido-
bacterium spp. can ameliorate dyslipidemia 
(Banjoko et al., 2012; Wang et al., 2013a). 
In obese and/or dyslipidemic patients, ad-
ministration of the LAB probiotic mixture 
ameliorated the levels of total cholesterol 
and LDL-cholesterol (Jones et al., 2013; 
Rai et al., 2013; Tuohy et al., 2014). The ef-
fects Lactobacillus reuteri GMNL-263 
(Lr263), a new probiotic strain developed 
by Hsieh’s laboratory, on insulin resistance 
and the development of hepatic steatosis in 
high-fructose fed rats were explored (Hsieh 
et al., 2013). The levels of serum glucose, 
insulin, leptin, C-peptide, glycated hemo-
globin, GLP-1, liver injury markers, lipid 
profile in serum and liver were significantly 
increased in high-fructose-fed rats (Hsieh et 
al., 2013). However, after Lr263 admin-
istration, the elevation of these parameters 
was significantly suppressed (Hsieh et al., 
2013). Therefore, the Hsieh’s study provid-
ed evidences clarifying the effectiveness of 
Lr263 on reducing insulin resistance as well 
as hepatic steatosis formation in high-
fructose-fed rats and suggested that Lr263 
may be a promising therapeutic agent in 
treating type 2 diabetes (Hsieh et al., 2013). 
Experimental evidence revealed that obesi-
ty-associated NAFLD is linked to changes 
in intestinal permeability and translocation 
of bacterial products to the liver (Ritze et 
al., 2014). Actually, no reliable therapy is 
available except for weight reduction. Ritze 
et al. (2014) examined the possible effect of 
the probiotic bacterial strain Lactobacillus 
rhamnosus GG (LGG) as protective agent 
against experimental NAFLD in a mouse 
model. LGG increased beneficial bacteria 
in the distal small intestine. Moreover, 
LGG reduced duodenal IκB protein levels 
and restored the duodenal tight junction 
protein concentration (Ritze et al., 2014). 
Ritze et al. showed for the first time that 
LGG protects mice from NAFLD induced 
by a high-fructose diet. The underlying me-
chanisms of protection likely involve an in-
crease of beneficial bacteria, restoration of 
gut barrier function and subsequent attenua-
tion of liver inflammation and steatosis 
(Ritze et al., 2014). Rosberg-Cody et al. 
(2011) demonstrated that a single gene (en-
coding linoleic acid isomerase) expressed in 
an intestinal microbe can influence the fatty 
acid composition of host fat.  
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Anti-inflammatory effects  
Probiotics have several anti-inflam-
matory effects (Table 1) that could contrib-
ute to clinical benefit in NAFLD (Ritze et 
al., 2014): competition with and displace-
ment of pathogenic strains in SIBO, par-
ticularly those with limited adherence abil-
ity in vitro (Abedi et al., 2013); alteration of 
inflammatory pathways produced by intes-
tinal bacterial overgrowth via alteration of 
cytokine signalling (Audy et al., 2012); 
amelioration of intestinal barrier function 
through modulation of cytoskeletal and 
tight-junction proteins (Miyauchi et al., 
2013; Noda et al., 2013); enhancement of 
the integrity of the intestinal epithelium by 
providing essential nutrients, especially in 
the form of medium-chain fatty acids that 
inhibit apoptosis (Wen et al., 2012); direct 
inhibition of the production of pro-inflam-
matory mediators, such as TNF and induc-
tion of anti-inflammatory responses in in-
testinal-epithelial-cell–leukocyte co-cultu-
res (Trapecar et al., 2014); and stimulation 
of IgA release (Ashraf and Shah, 2014). 
In conventional culture there was no 
Escherichia Coli bacterial translocation in 
control animals (Eizaguirre et al., 2011). 
Polymerase chain reaction detected Esche-
richia Coli bacterial translocation showing 
higher sensitivity (Eizaguirre et al., 2011). 
Administration of Lactobacillus johnsonii 
La1, without addition to antioxidants, not 
reduced bacterial translocation and not at-
tenuated endotoxemia in a rat model of cir-
rhosis (Soriano et al., 2012). Furthermore, 
mouse models of acute hepatitis have too 
showed reductions in the incidence of bac-
terial translocation and hepatic injury after 
the administration of several strains of Lac-
tobacillus and Bifidobacterium (Osman et 
al., 2007; Ahrne and Hagslat, 2011).  
 
FUTURE DIRECTIONS 
The importance of gut–liver interactions 
is also accentuated by the role of the intes-
tinal microbiota in NAFLD. The gut micro-
biota and SIBO, in particular, are now con-
sidered to be crucial factors in the patho- 
Table 1: Probiotics and clinical benefit in 
NAFLD 
Metabolic effects 
• Reduction availability of calories from 
indigestible carbohydrates  
• Enhancement insulin sensitivity  
• Modulation intraluminal bile salt me-
tabolism 
• Lower cholesterol 
• Production conjugated linoleic acid 
• Reduction hepatic fatty acid oxidation 
Anti-inflammatory effects 
• Competition with and displacement 
pathogenic strains in small intestinal 
bacterial overgrowth 
• Antibacterial effects mediated by 
bacteriocins 
• Modulation inflammatory pathways 
induced by bacteria involved in intes-
tinal bacterial overgrowth 
• Amelioration intestinal barrier func-
tion 
• Enhancement integrity of the intesti-
nal epithelium 
• Direct inhibition of the production of 
pro-inflammatory mediators and in-
duction anti-inflammatory responses 
• Stimulation release of 
immunoglobulin A 
 
genesis of NAFLD. Actually, evidence has 
been widely derived from a variety of ani-
mal models; the definition and diagnosis of 
SIBO in man continues to present a sub-
stantial challenge. 
Several bacterial components and prod-
ucts have been implicated in the pathogene-
sis of NAFLD and NASH; in animal mod-
els the role of lipopolysaccharide, through 
its capacity to regulate metabolic processes 
and activate proinflammatory cytokine pro-
duction, has been particularly prominent.  
Since it is clear, from everything that 
has been described above, the possible im-
portant role of gut derived microbial factors 
in the development and/or progression of 
NAFLD, a logical proposition is that modi-
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fying the microbiota might have a benefi-
cial effect on this pathological condition. 
Complications of liver disease could 
probably be reduced by altering the micro-
biota either qualitatively or quantitatively. 
For example, alteration of the gut microbio-
ta by prebiotics or probiotics might be an 
important therapeutic strategy in the treat-
ment of NAFLD. 
To understand the impact of gut mi-
crobes on human health and well-being it is 
crucial to assess their genetic potential (Qin 
et al., 2010). The gene set, approximately 
150 times larger than the human gene com-
plement, contains an overwhelming majori-
ty of the prevalent (more frequent) microbi-
al genes of the cohort and probably includes 
a large proportion of the prevalent human 
intestinal microbial genes (Qin et al., 2010).  
Several issues remain to be determined: 
the exact prevalence of SIBO (defined us-
ing modern molecular techniques) in 
NAFLD and NASH, whether the transloca-
tion of bacterial products, such as LPs, 
across the gut wall is significant to these 
disorders in man and whether tailored in-
terventions (with probiotics, prebiotics, an-
tibiotics, or some combinations thereof) 
will exert meaningful benefits.  
Alcohol consumption increases the 
SIBO and intestinal permeability of endo-
toxin (Abhilash et al., 2014). The endotoxin 
mediated inflammatory signaling plays a 
major role in alcoholic liver fibrosis (Abhi-
lash et al., 2014). The possible mechanism 
may be the inhibitory effect of acid ascorbic 
on SIBO, intestinal barrier defect and 
IKKβ, which decreased the activation of 
NF-κB and synthesis of cytokines, as re-
ported by Abhilash (Abhilash et al., 2014). 
SIBO is also responsible for endotoxemia, 
systemic inflammation, and its consequenc-
es including obesity and NAFLD (Duseja 
and Chawla, 2014). Relationship between 
gut microbiota and NAFLD is also depend-
ent on altered choline and bile acid metabo-
lism and endogenous alcohol production by 
gut bacteria (Duseja and Chawla, 2014). 
Further evidence linking gut microbiota 
with obesity and NAFLD comes from stud-
ies showing usefulness of probiotics in an-
imals and patients with NAFLD, as sug-
gested by Duseja et al. (Duseja and Chawla, 
2014).  
Diet and nutritional status are among 
the most important, modifiable determi-
nants of human health. The nutritional val-
ue of food is determined partially by a per-
son’s gut microbial community (microbio-
ta) and its component genes (microbiome). 
Separating the interactions between diet, 
the structure and operations of the gut mi-
crobiota, and nutrient and energy harvest is 
confounded by changes in human environ-
mental exposures, microbial ecology and 
genotype.  
The human gut microbiota and microbi-
al influences on lipid and glucose metabo-
lism, satiety, and chronic low-grade in-
flammation are known to be involved in 
metabolic syndrome (Remely et al., 2014). 
Fermentation end products, especially short 
chain fatty acids, are believed to engage the 
epigenetic regulation of inflammatory reac-
tions via free fatty acid receptor and other 
short chain fatty acid receptors. Remely et 
al. (2014) suggested that a different compo-
sition of gut microbiota in obesity and type 
2 diabetes affect the epigenetic regulation 
of genes. Interactions between the microbi-
ota and epigenetic regulation may involve 
not only short chain fatty acids binding to 
free fatty acid receptor. Therefore dietary 
interventions influencing microbial compo-
sition may be considered as an option in the 
engagement against metabolic syndrome 
(Remely et al., 2014). 
We hypothesized that each step in the 
process to ultimately bring gut microbiota 
manipulation to the clinic, in particular to 
harness its potential for the prevention and 
treatment of dysmetabolic disorders, needs 
to be a small, careful and well-controlled 
one, to be taken in the setting of expert 
multidisciplinary collaborations (Karlsson 
et al., 2013). The latter can only be an-
swered by appropriately powered, random-
ized, controlled clinical trials. Further stud-
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ies are required to investigate the human 
clinical potential of the probiotic formula-
tion in affecting the markers and pathogen-
esis of metabolic syndrome (Tomaro-Du-
chesneau et al., 2014), or associated mor-
bidities, according to recent findings show-
ing that modulation of gut microbiota by 
probiotics has beneficial effects on brain 
activity in stress conditions, displays an-
xiolytic-like activity and reduces apoptosis 
in the lymbic system in animal models of 
depression (Ait-Belgnaoui et al., 2013). 
This long-distance effect of probiotics 
opens up a new field of research mainly at 
the light of the possible impact on the un-
balance of apoptosis-antiapoptosis process , 
key mechanism inducing NAFLD/NASH 
(Tarantino et al., 2011). 
The main approach to obesity is to un-
ravel the mechanisms involved in nutrient 
absorption and then the role of gut flora. In 
conditions of over-nutrition, cells must 
cope with a multitude of extracellular sig-
nals generated by changes in nutrient load, 
hormonal milieu, adverse cytokine/adipo-
kine profile, and apoptosis/anti-apoptosis 
processes. To date studies have demonstrate 
that among all nutrients, lipids and carbo-
hydrates play a major regulatory role in the 
gene transcription of glycolytic and lipo-
genic enzymes (epigenetics), insulin, and 
adipokines. These nutrients mainly exert 
their effects through the gene expression of 
sterol responsive binding protein 1 and 2 
(SREBP) and the mammalian target of ra-
pamycin (mTOR) (Tarantino and Capone, 
2013). 
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